Ghana
Tuberculosis profile
| High HIV burden |
Population  2012 25 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.7 (0.88–2.9) 6.9 (3.5–11)
Mortality (HIV+TB only) 0.54 (0.49–0.63) 2.1 (1.9–2.5)
Prevalence  (includes HIV+TB) 23 (11–41) 92 (41–162)
Incidence  (includes HIV+TB) 18 (16–21) 72 (63–82)
Incidence (HIV+TB only) 2.8 (2.4–3.1) 11 (9.6–12)
Case detection, all forms (%) 81 (71–92)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 7 097 (49) Relapse 376 (45)
Smear-negative 5 668 (39) Treatment after failure 95 (11)
Smear-unknown / not done 311 (2) Treatment after default 93 (11)
Extrapulmonary 1 301 (9) Other 266 (32)
Other          
Total new 14 377   Total retreatment 830  
           
Other (history unknown)          
Total new and relapse 14 753   Total cases notified 15 207  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.1 1.6 1.5
Age < 15 81 518 221
Laboratories 2012
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.6
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 83  
Retreatment 77  
TB/HIV 2012 Number (%)
TB patients with known HIV status 11 825 (78)
HIV-positive TB patients 2 812 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 029 (72)
HIV-positive TB patients on antiretroviral therapy (ART) 1 033 (37)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
240 (13–440) 160 (61–260)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 44 (5%) 44
Laboratory-confirmed MDR-TB cases 0 20 20
Patients started on MDR-TB treatment     2
Financing TB control 2013
National TB programme budget (US$ millions) 38
% Funded domestically 9%
% Funded internationally 37%
% Unfunded 55%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data